Phytonadione Utilization and the Risk of Bleeding in Chronic Liver Disease

Overview

Journal Hosp Pharm

Publisher Sage Publications

Date 2024 Oct 28

PMID 39465095

Authors

Joanna He

Tessa R Cox

Brian W Gilbert

Affiliations

Soon will be listed here.

Abstract

To determine the safety and efficacy of phytonadione in patients with an elevated international normalized ratio (INR) secondary to chronic liver disease without active bleeding. This retrospective chart review compared hospitalized patients from 2015 to 2022 with a diagnosis of chronic liver disease, a baseline INR of 1.2 to 1.9, and without active bleeding who did or did not receive phytonadione. The primary outcome was the incidence of new bleeding. The incidence of thrombosis and change in INR were also evaluated. A total of 133 patients were included, of which 46 received phytonadione (mean 2.46 doses and mean dose 7.95 mg, 72.74% intravenously). Child-Pugh scores were higher in phytonadione patients (8.7 vs 9.93, = .0003). There was no difference in the incidences of new bleeding (9.20 vs 13.04%, = .492) or thrombosis (3.45 vs 0%, = .203) between the control and phytonadione groups. After phytonadione administration, there was no change in INR, while INR increased by 0.24 in the control group ( = .025). In chronic liver disease patients who were not bleeding, phytonadione did not reduce INR or the incidence of new bleeding.

References

Mucino-Bermejo J, Carrillo-Esper R, Mendez-Sanchez N, Uribe M . Thrombosis and hemorrhage in the critically ill cirrhotic patients: five years retrospective prevalence study. Ann Hepatol. 2014; 14(1):93-8. View

Al Sulaiman K, Al Mutairi M, Al Harbi O, Al Duraihim A, Aldosary S, Al Khalil H . Appropriateness of Using Vitamin K for the Correction of INR Elevation Secondary to Hepatic Disease in Critically ill Patients: An Observational Study. Clin Appl Thromb Hemost. 2021; 27:10760296211050923. PMC: 8646191. DOI: 10.1177/10760296211050923. View

Nanchal R, Subramanian R, Karvellas C, Hollenberg S, Peppard W, Singbartl K . Guidelines for the Management of Adult Acute and Acute-on-Chronic Liver Failure in the ICU: Cardiovascular, Endocrine, Hematologic, Pulmonary and Renal Considerations: Executive Summary. Crit Care Med. 2020; 48(3):415-419. DOI: 10.1097/CCM.0000000000004193. View

Aldrich S, Regal R . Routine Use of Vitamin K in the Treatment of Cirrhosis-Related Coagulopathy: Is it A-O-K? Maybe Not, We Say. P T. 2019; 44(3):131-136. PMC: 6385738. View

Llibre-Nieto G, Lira A, Vergara M, Sole C, Casas M, Puig-Divi V . Micronutrient Deficiencies in Patients with Decompensated Liver Cirrhosis. Nutrients. 2021; 13(4). PMC: 8069759. DOI: 10.3390/nu13041249. View

Smith C, Hennessey E, Crossey C, Crannage A . Impact of Vitamin K Administration on Elevated International Normalized Ratio in Chronic Liver Disease. Clin Appl Thromb Hemost. 2023; 29:10760296231164642. PMC: 10134161. DOI: 10.1177/10760296231164642. View

Garcia D, Crowther M . Reversal of warfarin: case-based practice recommendations. Circulation. 2012; 125(23):2944-7. DOI: 10.1161/CIRCULATIONAHA.111.081489. View

Bates D, Edwards J, Langevin A, Abu-Ulba A, Yallou F, Wilson B . Rebleeding in Variceal and Nonvariceal Gastrointestinal Bleeds in Cirrhotic Patients Using Vitamin K: The LIVER-K Study. Can J Hosp Pharm. 2020; 73(1):19-26. PMC: 7023928. View

Chapman A, Yerke J, Lumpkin M, Rudoni M, Militello M, Wang L . Evaluation of Response to High-Dose Intravenous Vitamin K Administration. Ann Pharmacother. 2023; 57(10):1178-1184. DOI: 10.1177/10600280231154246. View

10.

Sogaard K, Horvath-Puho E, Gronbaek H, Jepsen P, Vilstrup H, Sorensen H . Risk of venous thromboembolism in patients with liver disease: a nationwide population-based case-control study. Am J Gastroenterol. 2008; 104(1):96-101. DOI: 10.1038/ajg.2008.34. View

11.

Rivosecchi R, Kane-Gill S, Garavaglia J, Maclasco A, Johnson H . The effectiveness of intravenous vitamin K in correcting cirrhosis-associated coagulopathy. Int J Pharm Pract. 2017; 25(6):463-465. DOI: 10.1111/ijpp.12355. View

12.

McMurry H, Jou J, Shatzel J . The hemostatic and thrombotic complications of liver disease. Eur J Haematol. 2021; 107(4):383-392. PMC: 9009189. DOI: 10.1111/ejh.13688. View

13.

Ng V . Liver disease, coagulation testing, and hemostasis. Clin Lab Med. 2009; 29(2):265-82. DOI: 10.1016/j.cll.2009.05.001. View

14.

Dabbagh O, Oza A, Prakash S, Sunna R, Saettele T . Coagulopathy does not protect against venous thromboembolism in hospitalized patients with chronic liver disease. Chest. 2009; 137(5):1145-9. DOI: 10.1378/chest.09-2177. View

15.

Wu H, Nguyen G . Liver cirrhosis is associated with venous thromboembolism among hospitalized patients in a nationwide US study. Clin Gastroenterol Hepatol. 2010; 8(9):800-5. DOI: 10.1016/j.cgh.2010.05.014. View

16.

Meyer A, Green M, Pautler H, Korenblat K, Deal E, Thoelke M . Impact of Vitamin K Administration on INR Changes and Bleeding Events Among Patients With Cirrhosis. Ann Pharmacother. 2015; 50(2):113-7. DOI: 10.1177/1060028015617277. View

17.

Islam R, Kundu S, Jha S, Rivera A, Flores Monar G, Islam H . Cirrhosis and Coagulopathy: Mechanisms of Hemostasis Changes in Liver Failure and Their Management. Cureus. 2022; 14(4):e23785. PMC: 9063731. DOI: 10.7759/cureus.23785. View

18.

Amarapurkar P, Amarapurkar D . Management of coagulopathy in patients with decompensated liver cirrhosis. Int J Hepatol. 2011; 2011:695470. PMC: 3227517. DOI: 10.4061/2011/695470. View